Glycybridin C
Glycybridin C is a Protein tyrosine phosphatase 1B (PTP1B) inhibitor and pregnane X receptor (PXR) ligand. Glycybridin C inhibits insulin and leptin signaling pathway negative regulation, LPS (HY-D1056)-induced NF-κB transcriptional activity. Glycybridin C forms hydrophobic and π-π stacking interactions with Met243, Phe288, Tyr306, and His407 residues of PXR. Glycybridin C can be used for the research of hepatocellular carcinoma, colorectal adenocarcinoma, breast carcinoma.
For research use only. We do not sell to patients.
- CAS No.: 2088505-67-1
- Formula: C25H30O5
- Molecular Weight:410.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Glycybridin C (10 μM; 6 h) activates Nrf2 signaling in HepG2C8 cells[1].
Glycybridin C (10 μM; 24 h) shows weak inhibition of LPS-induced NO production in RAW 264.7 macrophages, with an inhibition rate of 4.1%[1].
Glycybridin C (10 μM; 6 h) inhibits LPS-induced NF-κB transcriptional activity in SW480 cells by 33.4%[1].
Glycybridin C (10 μM; 24 h) inhibits growth of HepG2, SW480, and MCF7 cells by 75.2%, 72.0%, and 82.1% respectively, while having no significant effect on A549 cells[1].
Glycybridin C (10 μM; 30 min) inhibits PTP1B activity by 37.7% in a cell-free assay[1].
Glycybridin C (10 μM; 15 min) does not inhibit tyrosinase activity in a cell-free assay[1].
Glycybridin C binds to the human PXR ligand-binding domain with a high predicted affinity, as indicated by a binding free energy of -67.93 kcal/mol[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2, SW480, A549, and MCF7 human cancer cell lines
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Inhibited cell growth by 75.2% in HepG2 cells.
Inhibited cell growth by 72.0% in SW480 cells.
Inhibited cell growth by 82.1% in MCF7 cells.
Showed no significant inhibition in A549 cells.
Chemical Information
-
CAS No. 2088505-67-1
-
Molecular Weight 410.50
-
Formula C25H30O5
-
SMILES
C/C(C)=C\CC(C=C1C[C@@H](O)C(C2=C(C(C/C=C(C)\C)=C(C=C2)O)O)=O)=C(C=C1)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Dual Luciferin reporter gene assay
Luciferin reporter gene assay is a reporting system to detect the activity of Firefly Luciferase using luciferin as a substrate, which is often used in the research of miRNA target gene verification and promoter transcriptive activity regulation. Dual luciferase usually refers to Firefly luciferase and Renilla luciferase.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
[1]. Li K, et al. Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra. J Nat Prod. 2017 Feb 24;80(2):334-346. [Content Brief]
[2]. Alhusban M, et al. Computational Tools to Expedite the Identification of Potential PXR Modulators in Complex Natural Product Mixtures: A Case Study with Five Closely Related Licorice Species. ACS Omega. 2022;7(30):26824-26843. Published 2022 Jul 21. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)